| |
|
|
ANOVA |
| |
HIT-Group (n=8) |
CMT-Group (n=7) |
(main effect) |
(main effect) |
(interaction) |
| Mean ( ± SEM) |
Mean ( ± SEM) |
Mean ( ± SEM) |
Mean ( ± SEM) |
training |
group |
(time x group) |
| |
Baseline |
Follow-up |
Baseline |
Follow-up |
P-value |
F-value |
P-value |
F-value |
P-value |
F-value |
| Weight (kg) |
84.9 ± 1.6 |
84.9 ± 4.7 |
96.1 ± 5.3 |
96.0 ± 5.3 |
0.29 |
1.07 |
0.13 |
2.60 |
0.58 |
0.33 |
| BMI (kg/m2) |
27.8 ± 1.0 |
27.7 ± 1.1 |
31.5 ± 1.6 |
31.6 ± 1.7 |
0.96 |
0.01 |
0.07 |
4.01 |
0.35 |
0.96 |
| HbA1C (%) |
7.1 ± 0.3 |
7.4 ± 0.3 |
6.9 ± 0.5 |
7.0 ± 0.4 |
0.07 |
3.55 |
0.78 |
0.09 |
0.41 |
0.71 |
| FPG (mg/dl) |
139.4 ± 11.1 |
146.3 ± 11.7 |
128.6 ± 13.4 |
129.9 ± 15.9 |
0.52 |
0.38 |
0.44 |
0.63 |
0.69 |
0.17 |
| HOMA-IR |
6.4 ± 2.0 |
7.2 ± 4.6 |
9.1 ± 2.9 |
11.4 ± 3.5 |
0.50 |
0.51 |
0.24 |
1.56 |
0.73 |
0.12 |
| CHOL (mg/dl) |
177 ± 11 |
185 ± 21 |
177 ± 18 |
168 ± 15 |
0.99 |
0.01 |
0.60 |
0.28 |
0.38 |
1.50 |
| HDL(mg/dl) |
50 ± 4 |
53 ± 5 |
44 ± 3 |
41 ± 3 |
0.78 |
0.03 |
0.08 |
3.52 |
0.09 |
3.33 |
| Hemoglobin (g/dl) |
13.7 ± 0.5 |
14.1 ± 0.5* |
14.5 ± 0.4 |
14.6 ± 0.4 |
0.01 |
11.07 |
0.35 |
0.93 |
0.04 |
5.25 |
Data are presented as mean ± SEM. *Significant changes within the group. Body mass index (BMI), glycosylated hemoglobine (HbA1C) fasting plasma glucose (FPG),
homeostasis model of assessment-insulin resistance (HOMA-IR), total serum cholesterol (CHOL), high-density lipoprotein cholesterol (HDL) |
